AEVI GENOMIC MEDICINE, INC. (LON:MEDG) Files An 8-K Regulation FD Disclosure
|Regulation FD Disclosure.|
On March 20, 2017, Aevi Genomic Medicine, Inc. (the Company)
issued a press release announcing topline results from the SAGA
trial of AEVI001 (oral nonstimulant) in adolescents with mGluR
mutation positive (mGluR ) ADHD. The press release is attached as
Exhibit 99.1 hereto and is incorporated herein by reference.
The Company hosted a conference call and live audio webcast on
Monday, March 20, 2017 to discuss the results from the SAGA trial
of AEVI001. The Company referred to the slide presentation,
attached as Exhibit 99.2 and incorporated by reference herein, on
the conference call. The slide presentation, together with an
archive of the webcast, will also be available for 30 days after
the date of the conference call in the Investor section of the
Companys website at www.aevigenomics.com.
The information in this Item 7.01 disclosure, including Exhibit
99.1 and Exhibit 99.2, is being furnished and shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities under that Section. In
addition, the information in this Item 7.01 disclosure, including
Exhibit 99.1 and Exhibit 99.2, shall not be incorporated by
reference into the filings of the Company under the Securities
Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing.
|Item 9.01.||Financial Statements and Exhibits.|
(d) Exhibits. The following exhibits are furnished herewith:
Aevi Genomic Medicine, Inc. Press Release dated March 20,
Slide Presentation dated March 20, 2017 (furnished to Item
About AEVI GENOMIC MEDICINE, INC. (LON:MEDG)
Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The Company’s product candidates include AEVI-001 and AEVI-002. The Company’s research and development efforts leverage an internal genomics platform and a collaboration with the Center for Applied Genomics (CAG) at The Children’s Hospital of Philadelphia (CHOP). . AEVI GENOMIC MEDICINE, INC. (LON:MEDG) Recent Trading Information
AEVI GENOMIC MEDICINE, INC. (LON:MEDG) closed its last trading session at 0.0000 with shares trading hands.